Introduction {#S1}
============

Bipolar disorder (BD), like other mental illnesses, is considered a disease caused by abnormal development of the nervous system. During the neural development of patients, the ganglion birth and death rates increased ([@B67]). According to the world health organization (WHO) statistics on BD, it is the sixth leading cause of disability worldwide.

The primary symptom of BD is a pathological increase or decrease in emotional activity, and the pathological process is a recurrent episode of mania and depression. The characteristics of mania are high mood, marked acceleration of thinking, and increased verbal movements. Conversely, depression often leads to low mood, slow thinking, reduced speech and movement, and loss of appetite ([@B12]). Thus, the alternation of these two diseases can significantly impact the health of the patient. BD can cause circadian rhythm disturbances ([@B20]), cognitive impairment, verbal memory loss ([@B7]), and increase the risk of other diseases. Suicide ([@B6]) is the leading cause of death in BD patients. In one long-term study, the average suicide rate of major emotional patients was 15--20%, and while BD patients had a rate of more than 20% ([@B54]). Furthermore, the suicide of a patient can greatly affect their family and society.

Bipolar disorder has a high rate of misdiagnosis, prevalence and mortality. As the clinical manifestations of unipolar and bipolar depression are difficult to distinguish, and unipolar depression is more common ([@B22]). Therefore, it is crucial to find the hub genes that influence BD to improve the current treatment status. The prefrontal cortex is often called the center of the command and emotional control of the brain and is inextricably linked to mental illness. Microarray analysis of gene expression profiles in the prefrontal cortices from BD patients might contribute to the identification of hub genes and key pathways related to BD supporting the development of a new treatment strategy.

Weighted gene co-expression network analysis (WGCNA), which has been proposed by scholars [@B74], is a highly efficient and accurate biological methodology for Microarray data. The WGCNA package was released in 2008 ([@B35]). To date, related studies have preformed gene expression microarray profiling of diseases to identify the hub genes related to diseases based on WGCNA, including osteoporosis ([@B17]), hepatocellular carcinoma ([@B72]), osteosarcoma ([@B40]), and renal cell carcinoma ([@B9]).

Weighted gene co-expression network analysis has been used to analyze large gene data sets. Build a matrix of all the genes and soft threshold of the data set is performed, and then the scale-free network is established through the soft threshold ([@B35]). Tens of thousands of genes are divided into different modules in scale-free networks, and the genes in each module have the same expression pattern. After correlating these modules with the phenotypic characteristics of the sample, modules with a high correlation with the sample features are selected. Finally, hub genes with high connectivity in the module were identified. These genes play key roles in the characteristics and the development of the disease. Thus, the aim of the present study was to find the hub genes, key pathways, and potential molecular mechanisms of BD.

Materials and Methods {#S2}
=====================

Data Collection and Pre-processing {#S2.SS1}
----------------------------------

The gene expression microarray profile of BD was obtained from the gene expression omnibus (GEO) database^[1](#footnote1){ref-type="fn"}^ ([@B4]). There were 205 samples in the data set of GSE53987 ([@B36]), including 48 patients with schizophrenia, 52 patients with BD, 50 patients with major depressive disorder, and 55 healthy individuals. Each state is divided into the pre-frontal cortex, striatum, and hippocampus, depending on the tissue source. In this study, we selected 36 samples, including 17 BD and 19 healthy controls (HC). All samples were derived from Postmortem human sample's pre-frontal cortex, and the BD group was indistinguishable from the HC group in mean age, postmortem interval, brain pH, RNA integrity number (RIN). All tissue samples were based on the platform of the Affymetrix Human Genome U133 Plus 2.0 Array. Robust multi-array averaging (RMA) algorithm was used to process the original file to ensure the comparability of gene expression profiles ([@B24]). The nsFilter algorithm was used to remove the probes that had little variation in the expression value, as well as the probes that did not have a corresponding gene ID ([@B72]).

Co-expression Network Construction {#S2.SS2}
----------------------------------

Weighted gene co-expression network analysis package was necessary for the co-expression network construction ([@B35]). First, the function goodSamplesgenes was used to remove unqualified genes and samples, and Z.k \< −2.5 was excluded from subsequent studies. Then, function pickSoftThreshold was used to choose an appropriate soft-thresholding power (β) based on a scale-free topology criterion. The weighted adjacency matrix was constructed using the soft-thresholding power. The relationship between one gene and all other ones in the analysis was incorporated, and the adjacency matrix was transformed into the topological matrix (TOM) ([@B73]). The genes demonstrated hierarchical clustering using the flashClust function, according to the TOM-based dissimilarity (1-TOM) measure. After hierarchical clustering, highly interconnected genes were assigned to the same module ([@B57]).

Identification of Clinically Significant Modules and Functional Annotation {#S2.SS3}
--------------------------------------------------------------------------

After the effective clinical information was imported into the co-expression network, the module eigengene (ME), gene significance (GS), and module membership (MM) were calculated. ME was representative of the gene expression profiles in a module, representing the average expression level of genes in this module. MM was defined as the degree of correlation between genes and module. If MM is close to 0, then the gene is not part of the module. Conversely, if MM is close to 1 or −1, the gene is highly correlated with the module. GS can be considered to be the association of individual genes with clinical information. The module could be a candidate if it has a high ME valve with the clinical trait ([@B35]). The annotating the function of relevant modules was preformed to the potential mechanisms for the effects of corresponding clinical symptoms. All genes in the candidate modules were uploaded to the Enrichr database ([@B34]) for pathway enrichment based on gene ontology (GO) functional annotation and the kyoto encyclopedia of genes and genomes (KEGG). GO enrichment analysis is primarily divided into three parts, molecular function (MF), biological process (BP), and cellular component (CC).

Identification and Validation of Hub Gene {#S2.SS4}
-----------------------------------------

Hub genes are defined as genes with high correlation in candidate modules. High connectivity means that the connectivity ranked at top 10%. For example, if the module size was 1000, then the genes with top 100 were defined as the hub genes. Moreover, the hub gene has to meet the absolute value of the geneModuleMembership \>0.80 and geneTraitSignificance \>0.20. After identifying hub genes highly associated with clinical traits, search tool for the retrieval of interacting genes (STRING) ([@B64]) database was used to construct a PPI network and Cytoscape and ([@B60]) visualize the PPI network. If a gene has high degrees in a PPI network, it will be defined as playing a critical role in the module. At last, hub genes selected will be validated. A separate dataset GSE12649 ([@B25]) was used to verify the differential in the expression of hub genes in clinical traits using one-way ANOVA (*P* \< 0.05). In order to prevent the gender and age of the sample having an impact on the selected hub genes, we used one-way covariance analysis to detect it.

Results {#S3}
=======

Data Pre-processing and Co-expression Network Construction {#S3.SS1}
----------------------------------------------------------

We downloaded 36 raw files from BD patients' pre-frontal cortex from the GEO database. A total of 10094 genes were obtained from 36 samples through the RMA algorithm and nsFilter. In subsequent studies, samples GSM1304927 and GSM1304952 were filtered out ([Supplementary Figure 1](#SM1){ref-type="supplementary-material"}). On the basis of the scale-free topology criterion, to define the adjacency matrix, we selected β = 6 which the scale-free topology fit index reaches 0.88 as the soft-thresholding power ([Supplementary Figure 2](#SM1){ref-type="supplementary-material"}). As shown in [Supplementary Figure 3](#SM1){ref-type="supplementary-material"}, the 10,094 genes were divided into 19 modules based on the dynamic tree cutting method.

Identification of Clinically Significant Modules and Functional Annotation {#S3.SS2}
--------------------------------------------------------------------------

After the clinical traits of the samples were introduced into the weighted network ([Figure 1](#F1){ref-type="fig"}), The study found Pink (*r* = 0.51, *P* = 0.002) module with 221 genes, brown (*r* = 0.42, *P* = 0.01) with 1104 genes, and midnightblue module (*r* = −0.41, *P* = 0.02) with 138 genes were highly correlated with the disease. In the following analysis, the GS and MM of the midnight blue module (cor = 0.51, *P* = 1.7e-10, [Figure 2](#F2){ref-type="fig"}), the brown module (cor = 0.44, *P* = 1.3e-53, [Figure 2](#F2){ref-type="fig"}) and the pink module (cor = 0.48, *P* = 4.8e-16, [Figure 2](#F2){ref-type="fig"}) were calculated. In order to clarify the functional mechanism of targeted modules and diseases, 143 hub genes were uploaded to the Enrichr database for functional annotation. [Supplementary Table 1](#SM1){ref-type="supplementary-material"} shows clear information about 143 hub genes. GO function annotation indicates that hub genes were enriched in eye development, G-protein coupled receptor complex, positive regulation of transcription, negative regulation of canonical Wnt signaling pathway, cytokine receptor activity complex, activating transcription factor binding, phosphatidylinositol binding, and others (*P* \< 0.01) ([Supplementary Table 2](#SM1){ref-type="supplementary-material"}). [Supplementary Table 3](#SM1){ref-type="supplementary-material"} shows that hub genes were enriched in the Hippo signaling pathway, thyroid hormone signaling pathway, signaling pathways regulating stem cell pluripotency, endocytosis, adherens junction, and others, based on KEGG pathway analysis (*P* \< 0.01).

![Module-trait relationships. Stage indicated bipolar disorder (BD) and non-BD.](fphys-10-01081-g001){#F1}

![Scatter diagram for module membership vs. gene significance of stage (BD or non-BD) in three modules.](fphys-10-01081-g002){#F2}

Validation of Hub Gene and PPI Network Construction {#S3.SS3}
---------------------------------------------------

We use the methods mentioned above to identify hub genes. 143 hub genes in the three modules were identified. [Figure 3](#F3){ref-type="fig"} shows the PPI network for modules which are a candidate. The module network contained 96 nodes and 160 edges, three of which were identified as the high degree genes. Moreover, we found that hub genes with better connectivity in the PPI network are significantly enriched in the positive regulation of transcription (DNA-templated), including SOX2, FGF2, SMAD2, YAP1, PAX6, AGT, and FOXO1. This enrichment pathway might be a potential BD mechanism. All hub genes were validated based on GSE12649. Finally, we identified 30 hub genes common to both data sets as our final hub genes. Boxplots were used to show the validation results for 30 hub genes ([Figure 4](#F4){ref-type="fig"}). [Table 1](#T1){ref-type="table"} shows final hub genes in the three modules, and the covariate analyses of final hub genes are described in [Supplementary Table 4](#SM1){ref-type="supplementary-material"}.

![PPI network for all candidate modules.](fphys-10-01081-g003){#F3}

![Boxplot for identification of hub genes in the three modules.](fphys-10-01081-g004){#F4}

###### 

Hub genes from the interesting modules.

  **Gene symbol**   **ENTREZ_GENE_ID**   **Gene ontology**                                           **geneModuleMembership**   **Gene trait significance**   **Up or down**
  ----------------- -------------------- ----------------------------------------------------------- -------------------------- ----------------------------- ----------------
  AGT               183                  Alkylguanine DNA binding                                    0.887157454                0.298842057                   Down
  AHCYL1            10768                Adenosylmethionine hydrolase activity                       0.892921034                0.263587391                   Down
  APOE              348                  Cognition                                                   0.906508824                0.259473598                   Down
  ATP1A2            477                  Temperature gated cation channel activity                   0.944732073                0.358469425                   Down
  CHRDL1            91851                Negative regulation of secondary growth                     0.863182953                0.462817741                   Down
  EMX2              2018                 Forebrain neuroblast differentiation                        0.943545349                0.339285953                   Down
  ETNPPL            64850                /                                                           0.905878301                0.312454124                   Down
  FAM189A2          9413                 Gene expression                                             0.872771128                0.313792924                   Down
  FGF2              2247                 fibroblast proliferation                                    0.9348346                  0.45704696                    Down
  GJA1              2697                 Gap junction                                                0.920113458                0.328482543                   Down
  GNA12             2768                 Spermatid nucleus differentiation                           0.867055073                0.311316484                   Down
  HEPH              9843                 Copper exporting atpase activity                            0.959262811                0.384839787                   Down
  IL17RB            55540                Cardiac fibroblast cell fate commitment                     0.87323481                 0.315545635                   Down
  MAOA              4128                 Monoamine oxidase activity                                  0.889016805                0.495684                      Down
  METTL7A           25840                RNA polymerase II regulatory region DNA binding             0.93466073                 0.322509631                   Down
  NOTCH2            4853                 Notch signaling pathway                                     0.952637565                0.360026782                   Down
  NTRK2             4915                 Regulation of neurotrophin TRK receptor signaling pathway   0.947485184                0.327326464                   Down
  PARD3             56288                Positive regulation of JAK STAT cascade                     0.877332438                0.357811988                   Down
  PAX6              5080                 Eye development                                             0.912624234                0.408751454                   Down
  PDLIM5            10611                Activation of bipolar cell growth                           0.92796358                 0.456391993                   Down
  PPAP2B            8613                 Cell migration involved in coronary angiogenesis            0.882924502                0.299775962                   Down
  RAB31             11031                ER body                                                     0.908780797                0.376400336                   Down
  SDC2              6383                 Positive regulation of synapse maturation                   0.935916785                0.333198546                   Down
  SDC4              6385                 Small molecule catabolic process                            0.889206651                0.361762932                   Down
  SLC1A3            6507                 Negative regulation of L glutamate transport                0.930712467                0.322178332                   Down
  SMAD2             4087                 SMAD2 protein complex                                       0.841744744                0.431128371                   Down
  SOX2              6657                 Stem cell differentiation                                   0.960030288                0.437884345                   Down
  TP53BP2           7159                 P53 binding                                                 0.916365941                0.261334186                   Down
  YAP1              10413                Hippo signaling                                             0.946460117                0.317467764                   Down
  YES1              7525                 Regulation of B cell antigen processing and presentation    0.913582422                0.40331199                    Down

Discussion {#S4}
==========

Bipolar disorder, a disease that is spread worldwide, has high rates of disability ([@B68]), mortality, and suicide, which can impose a significant burden on society ([@B1]). Therefore, exploring the hub genes and key pathways related to BD is essential for the diagnosis and treatment of patients with BD.

The weighted gene co-expression network analysis algorithm searches for effective information from gene expression microarray profile by building gene modules, and it tries to explain the significance of a gene module from the perspective of biology. In this study, we found that the pink, midnightblue, and brown modules were highly correlated with BD or no-BD. The expression of 30 genes in these three modules showed significant changes in patients with BD and non-BD individuals, 25 of which were validated through one-way ANOVA. Although other five genes have not been validated, most of them have been mentioned in previous studies ([@B45]; [@B44]; [@B19]). These hub genes may have important clinical significance in the course of BD patient diagnosis and prognosis. After covariate analysis of all hub genes, we found that gender had little effect on these genes (*P* \> 0.05). A few hub genes are affected by age factors (*P* \> 0.05), including SCD4, PDLIM5, FAM189A2, and MAOA.

Kyoto encyclopedia of genes and genomes enrichment analysis suggested that the hub gene is mainly enriched in the Hippo signaling pathway, thyroid hormone signaling pathway, adherens junction, endocytosis, cell adhesion molecule, and mineral absorption. Meanwhile, we found that SMAD2 (SMAD family member 2), a member of the SMAD family, appears in most enrichment pathways. SMAD proteins are signal transducers and transcriptional modulators that mediate multiple signaling pathways. SMAD proteins regulate the signaling of transforming growth factor (TGF)-beta, and it plays a vital role in the growth, repair, and rotation of the nervous system ([@B38]).

The primary role of the Hippo signaling pathway is to regulate cell growth and apoptosis, maintaining organ size ([@B75]). Moreover, it has another role in the establishment and maintenance of dendritic fields, since abnormalities in the Hippo signaling pathway can cause defects in these functions ([@B15]). There is a significant difference in the dendritic structure between BD patients and normal individuals ([@B33]). The hub gene YAP1 (Yes-associated protein 1) is the main effector downstream of the Hippo signal pathway ([@B46]). Abnormalities in YAP1 expression will affect the function of the Hippo signal pathway. Also, YAP1 plays an essential role in the maintenance of neural progenitor cells ([@B46]). Neural progenitor cells regulate the production of the cerebral cortex ([@B2]). The hub gene PARD3 (par-3 family cell polarity regulator) and Hippo signaling pathway together maintain ordered RGP (radial glial progenitor) splitting behavior and neuron generation in the mammalian cortex, and asymmetric division of RGPs regulates the generation of cortical neurons ([@B31]; [@B39]). Dysfunction of this mechanism often leads to cortical neuron damage and may lead to the development of BD. Moreover, a recent study also mentioned that BD is associated with the Hippo signaling pathway ([@B50]).

Gene ontology function annotation indicates that hub genes are significantly represented in some biological processes such as eye development, G-protein coupled receptor complex, positive regulation of transcription, negative regulation of canonical Wnt signaling pathway, cytokine receptor activity, and activating transcription factor binding. The Wnt signaling pathway contributes to the development of neural circuits and neuronal plasticity as well as early neural induction ([@B28]; [@B62]; [@B11]). Neurodevelopmental disorders are often one of the main pathological features of mental illness. There is already a large body of evidence confirming that abnormalities in the Wnt signaling pathway contribute to BD pathogenesis ([@B48]). We have obtained many biological processes through GO enrichment analysis, and although many of them have not been mentioned, these may be potential mechanisms underlying the development of BD.

For the PPI network, we found significant connectivity between the three genes, including SOX2 (SRY-box 2), FGF2 (fibroblast growth factor 2), and APOE (apolipoprotein E). SOX2 is a transcription factor that regulates stem cell proliferation and differentiation in the central nervous system ([@B52]; [@B32]). Moreover, the SOX2-encoded product SOX2ot is considered to be a potential marker of neurodegenerative diseases ([@B3]). FGF2 plays a crucial role in maintaining differentiation and function of the central nervous system ([@B69]), and the level of FGF2 in patients with BD is higher than that in healthy people ([@B41]). NOTCH2 (notch receptor 2) plays a key role in the development of the nervous system ([@B63]). A series of pathological and behavioral changes in BD patients may indicate that the development of the nervous system has been destroyed ([@B51]). FGF2 can inhibit neuronal differentiation through the NOTCH pathway ([@B18]), which may affect the normal development of the nervous system, leading to BD. APOE apolipoprotein plays a key role in maintaining cerebral phospholipid homeostasis ([@B77]) and plays a vital role in the pathogenesis and pathology of Alzheimer's disease (AD) ([@B56]). SLC1A3 (solute carrier family 1 member 3) plays a role in the termination of excitatory neurotransmission in the central nervous system. SLC1A3 has been shown to decrease in BD patients ([@B44]). NTRK2 (neurotrophic receptor tyrosine kinase 2) is thought to have the effect of a mood stabilizer, which may affect the treatment of BD ([@B16]). It is a receptor for neurotrophin brain-derived neurotrophic factor (BDNF). BDNF has nutritional and protective effects on nerves and is a potential biomarker for BD ([@B59]; [@B49]). NTRK2 is considered a candidate gene for BD ([@B61]). AGT (angiotensinogen) was found to be associated with increased susceptibility to BD in Brazil ([@B45]).

Coincidentally, many genes with high connectivity in the PPI network were enriched in the positive regulation of transcription (DNA-templated), including SOX2, FGF2, SMAD2, YAP1, PAX6, AGT, and FOXO1. In a recent study, BD IPSC (induced pluripotent stem cells) is significantly different from normal IPSC in gene expression profiling, especially membrane receptor and ion channel genes, and calcium ion-related transcripts ([@B8]). It is well known that miRNA is one of the products of the transcription process, and miRNA expression level is closely related to transcriptional regulation. The expression levels of multiple MIRNAs in the prefrontal cortex of BD patients have changed ([@B29]; [@B47]). The expression profile of astrocytes in the cerebral cortex of patients with BD has also increased ([@B65]). The activity of the transcription factor plays an essential role in neuronal function. Abnormal gene expression of transcription factors can affect the development and function of the nervous system and may lead to mental diseases, including BD ([@B53]).

Gap junction protein alpha 1 (GJA1) is a member of the connexin gene family, encodes connexin (Cx) proteins, Cx43 ([@B13]). GJA1 is widely expressed in astrocytes, mice lacking GJA1 are grossly normal, but their synaptic plasticity is reduced ([@B21]). The development of BD also leads to changes in synaptic plasticity ([@B5]), and BD pathology is associated with apoptosis and synaptic dysfunction ([@B30]). Moreover, the traditional therapeutic drug lithium agent of BD has a potential effect on the activation of neural plastic channels during the treatment process ([@B42]). However, there is currently no evidence that BD is associated with GJA1.

Both Bipolar disorder and Alzheimer's disease are neurologically related diseases, one is neurodevelopmental disorder ([@B58]), and the other is neurodegeneration ([@B23]). But they have related pathophysiological processes ([@B43]), and some of the disease-causing genes are overlapping ([@B14]). In our results, 16 of the 30 hub genes are related to AZ. Among them, AGT, APOE, GJA1, MAOA, RAB31, NOTCH2, PDLIM5, SLC1A3, SMAD2, and YAP1 are biomarkers or related risk factors of AZ ([@B70]; [@B66]; [@B27]; [@B10]; [@B26]; [@B37]; [@B55]; [@B71]; [@B76]). This further proves that there may be a certain relationship between BD and AZ, with overlapping mutant genes.

To the best of our knowledge, this is the first WGCNA analysis of RNA data from tissues of the prefrontal cortex of BD patients. The primary advantage of this study is to combine the gene expression data of BD patients with clinical traits. By choosing the appropriate weighting coefficient to weight the correlation coefficient between genes, the WGCNA algorithm could make the gene network obey the scale-free network distribution and divide the genes with similar expression into the same module. Then, the modules with high correlation with traits were selected, and hub genes in the modules were identified. Finally, the potential relationship between modules and hub genes and traits was further discussed through gene enrichment analysis.

Our research has some limitations. Compared to previous WGCNA analyses of other disease, our sample size was insufficient, and there might be some bias. Nevertheless, we were able to replicate many published findings successfully, and we used a separate database to verify the experimental results. Although most hub genes were verified, a few hub genes were not, probably because the samples of GSM12649 were not from the same platform. Another limitation is that similar studies have been published. However, we have discovered many new hub genes and enrichment pathways. Future studies will involve more experiments to prove and explain how hub genes and hub pathways affect BD development.

Conclusion {#S5}
==========

Our study based on WGCNA analyses found the 30 hub genes in three modules related to BD, and the Hippo signaling pathway and positive regulation of transcription may be one of the potential BD mechanisms. These hub genes and enrichment pathways may have important clinical implications for BD treatment and diagnosis.
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